<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844125</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1209-303</org_study_id>
    <nct_id>NCT04844125</nct_id>
  </id_info>
  <brief_title>SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research</brief_title>
  <official_title>A Multicentric, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with&#xD;
      hypercholesterolemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Background Lipolowering therapy in combination with SHR-1209/ placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 weeks Percentage change in serum LDL-C levels from baseline.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 weeks Absolute Changes in serum LDL-C levels from baseline；</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 weeks Percentage change of non-HDL-C relative to baseline；</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>SHR-1209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1209 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209</intervention_name>
    <description>SHR-1209</description>
    <arm_group_label>SHR-1209</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209 Placebo</intervention_name>
    <description>SHR-1209 Placebo</description>
    <arm_group_label>SHR-1209 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any male or female aged between 18 and 80 on the date of signing the informed consent;&#xD;
&#xD;
          2. Diagnosed as hypercholesterolemia ;&#xD;
&#xD;
          3. Fasting triglyceride was less than 5.6 mmol/L during screening:&#xD;
&#xD;
          4. Understand the study procedures and methods, volunteer to participate in the study,&#xD;
             and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of the following diseases or treatments during the screening period:&#xD;
&#xD;
               1. Known allergies to PCSK9 inhibitors or test drugs, or severe allergic reactions&#xD;
                  to other antibody drugs in the past;&#xD;
&#xD;
               2. Participated in clinical studies of other drug interventions within the last 1&#xD;
                  month (except for patients who failed in screening), or those who are within 5&#xD;
                  half-lives of the drug before screening (whichever is longer);&#xD;
&#xD;
          2. Any of the laboratory test indicators meets the following criteria:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) was more than&#xD;
                  3 times the upper limit of normal value (ULN), and total bilirubin was more than&#xD;
                  2 times ULN during the screening period or at random;&#xD;
&#xD;
               2. The creatine kinase (CK) was more than 3 times of ULN during the screening period&#xD;
                  or at random;&#xD;
&#xD;
          3. Have used the following drugs:&#xD;
&#xD;
               1. PCSK9 inhibitors had been used in the previous 6 months;&#xD;
&#xD;
               2. Continuous systemic corticosteroid therapy with doses exceeding or equivalent to&#xD;
                  10mg of prednisone (oral or intravenous) within the previous 3 months was&#xD;
                  screened.&#xD;
&#xD;
          4. Other circumstances:&#xD;
&#xD;
               1. Women of reproductive age who are fertile but did not use contraception within 4&#xD;
                  weeks before the screening period;Women who are pregnant or breastfeeding;Not&#xD;
                  agreed during the trial or at 24 weeks after the last dose&#xD;
&#xD;
               2. Subjects who are considered by the investigator to have any unsuitable factors&#xD;
                  for participating in the study or who have poor compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lijun Tang</last_name>
    <phone>+86 18570616501</phone>
    <email>xiaojian.gao@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojian Gao</last_name>
    <phone>+86 18510128450</phone>
    <email>xiaojian.gao@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiyan Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

